ALX Oncology Reports Interim Phase 2 ASPEN-06 Trial Data For Advanced HER2-Positive Gastric Cancer, Showing Confirmed Overall Response Rate Of 52% For Evorpacept Combo Treatment Versus 22% For Control Treatment
Portfolio Pulse from Benzinga Newsdesk
ALX Oncology has reported interim Phase 2 ASPEN-06 trial data for advanced HER2-positive gastric cancer. The data shows a confirmed overall response rate of 52% for Evorpacept combo treatment, compared to 22% for control treatment.
October 03, 2023 | 10:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ALX Oncology's Evorpacept combo treatment has shown promising results in the Phase 2 ASPEN-06 trial for advanced HER2-positive gastric cancer, which could potentially boost the company's stock.
The positive interim results from the Phase 2 ASPEN-06 trial for ALX Oncology's Evorpacept combo treatment could potentially lead to increased investor confidence and a rise in the company's stock price. The treatment's 52% response rate significantly outperforms the 22% response rate of the control treatment, indicating its potential effectiveness against advanced HER2-positive gastric cancer.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100